Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate single-dose PK of VIR-2218 following a SC injection
of VIR-2218 administered at a dose up to 200 mg in participants with liver cirrhosis with
various degrees of impaired hepatic function compared with healthy participants with normal
hepatic function.